Processa Pharmaceuticals's EBIT per Share for the
three
months ended in Mar. 2024 was $-1.14.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was $-6.51.
During the past 3 years, the average EBIT per Share Growth Rate was 20.20% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 4.90% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 25.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Processa Pharmaceuticals's EBIT per Share or its related term are showing as below:
PCSA'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -30.4 Med: 20.2 Max: 77.7
Current: 20.2
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Processa Pharmaceuticals was 77.70% per year. The lowest was -30.40% per year. And the median was 20.20% per year.
PCSA's 3-Year EBIT Growth Rate is ranked better than 70.97% of 1309
companies
in the Biotechnology industry
Industry Median: 3.6
vs PCSA: 20.20
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.51
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Processa Pharmaceuticals (NAS:PCSA) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Processa Pharmaceuticals EBIT per Share Related Terms
Thank you for viewing the detailed overview of Processa Pharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Processa Pharmaceuticals (Processa Pharmaceuticals) Business Description
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on the development of drug products that are intended to improve the survival and quality of life for patients who have an unmet medical need. The company's lead product, PCS499 is an oral tablet that is an analog of an active metabolite of an already approved drug. It focuses on fibrotic related diseases such as focal segmental glomerulosclerosis, idiopathic pulmonary fibrosis. Its pipeline products comprise PCS6422, PCS12852, and PCS100.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PCSA has been successfully added to your 